Severe Intraocular Inflammation After Intravitreal Injection of Faricimab: A Single-Site Case Series of Six Patients.

Autor: Ben Ghezala I; From the Ophthalmology Department (I.B.G., P-H.G., M.S., L-A.S., L.A., C.C-G.), University Hospital, Dijon, France; Inserm, CIC 1432 (I.B.G.), Clinical Investigation Center, Clinical Epidemiology/Clinical Trials Unit, University Hospital, Dijon, France. Electronic address: ines.ben-ghezala@chu-dijon.fr., Gabrielle PH; From the Ophthalmology Department (I.B.G., P-H.G., M.S., L-A.S., L.A., C.C-G.), University Hospital, Dijon, France; Eye and Nutrition Research Group (P-H.G., C.C-G.), CSGA, UMR1324 INRAE, 6265 CNRS, Dijon, France., Sibert M; From the Ophthalmology Department (I.B.G., P-H.G., M.S., L-A.S., L.A., C.C-G.), University Hospital, Dijon, France., Steinberg LA; From the Ophthalmology Department (I.B.G., P-H.G., M.S., L-A.S., L.A., C.C-G.), University Hospital, Dijon, France., Dautriche A; Burgundy Regional Pharmacovigilance Center (A.D.), University Hospital, Dijon, France., Arnould L; From the Ophthalmology Department (I.B.G., P-H.G., M.S., L-A.S., L.A., C.C-G.), University Hospital, Dijon, France., Creuzot-Garcher C; From the Ophthalmology Department (I.B.G., P-H.G., M.S., L-A.S., L.A., C.C-G.), University Hospital, Dijon, France; Eye and Nutrition Research Group (P-H.G., C.C-G.), CSGA, UMR1324 INRAE, 6265 CNRS, Dijon, France.
Jazyk: angličtina
Zdroj: American journal of ophthalmology [Am J Ophthalmol] 2025 Jan; Vol. 269, pp. 11-19. Date of Electronic Publication: 2024 Aug 10.
DOI: 10.1016/j.ajo.2024.08.008
Abstrakt: Purpose: To describe the patient characteristics and clinical course of severe intraocular inflammation (IOI) following intravitreal injection (IVT) of faricimab.
Design: Retrospective case series.
Methods: Case series at a single French academic center (Dijon University Hospital) where 263 patients were treated with faricimab IVT between January 9, 2024 and May 7, 2024.
Results: Over the 4-month period, a total of 1659 eyes (1338 patients) received anti-vascular endothelial growth factor (anti-VEGF) IVTs for a total of 3510 IVTs, of which 343 eyes (263 patients) received faricimab IVTs for a total of 971 IVTs. Overall, 6 pretreated eyes with neovascular age-related macular degeneration that were switched to faricimab developed severe unilateral IOI following faricimab IVT (1/162 injections [0.62%]), including 5 eyes presenting with a severe anterior and intermediate uveitis mimicking infectious endophthalmitis. All eyes were normotensive and presented with mild to moderate pain and predominantly moderate vitritis, associated with granulomatous keratic precipitates in 2 eyes and nonocclusive vasculitis in one eye. The clinical presentation, sterile vitreous sample culture, and rapid improvement with treatment made the diagnosis of infectious endophthalmitis unlikely. Four patients out of 6 did not recover their pre-IOI visual acuity, with an average visual loss of +0.2 logMAR. Two patients had positive antinuclear antibodies, including one with a history of cutaneous lupus.
Conclusions: In this case series, we reported 6 cases of severe IOI after intravitreal faricimab over 4 months in a single French center with an estimated incidence rate of 0.6% per injection. Future real-world data will contribute to a better evaluation of the epidemiology of this rare inflammatory adverse event related to intravitreal faricimab.
(Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE